Scientists at The Wistar Institute have unveiled part of the protein complex that protects telomeres—the ends of our chromosomes. The study, published online in Nature Communications, explains how a group of genetic mutations ...
Apr 11, 2017
0
172
A Massachusetts General Hospital (MGH) research team has found how a variant in an important epigenetic enzyme—previously associated by population-based genetic studies with Crohn's disease and other immune disorders—interferes ...
Mar 3, 2017
0
83
Leukemia affects 350,000 people worldwide. It is a cancer of the white blood cells, which are the cells of the immune system and are produced by stem cells in the bone marrow. There are two types of chronic and two types ...
Jan 27, 2017
0
2
A combination of two targeted agents - one approved by the Food and Drug Administration and one undergoing testing - has demonstrated safety as well as encouraging signs of effectiveness in a phase 1 clinical trial in patients ...
Dec 5, 2016
0
2
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, ...
Dec 3, 2016
0
1
Adoption of novel oral targeted therapies for treatment of chronic lymphocytic leukemia (CLL) could raise the treatment costs for the blood-system cancer in the U.S. by almost 600 percent. In their analysis in the Journal ...
Nov 21, 2016
0
0
Leukemia is a disease in which each cell can exhibit different genetic traits, and now Swedish researchers have found a cheap way to examine the individual cells. Reported in Nature Communications, the breakthrough could ...
Oct 14, 2016
0
1
Treating B cell malignancies with the patients' own T cells modified so as to target specific B cell markers has shown clinical success.
Jun 6, 2016
0
1
More precise dosing methods and cellular engineering techniques show promise in the effort to improve treatment of aggressive cancers with personalized cellular therapies, according to new studies from researchers in the ...
Jun 3, 2016
0
3
(HealthDay)—Venclexta (venetoclax) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL) characterized by a specific chromosomal abnormality called the 17p deletion.
Apr 11, 2016
0
0
